The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 08, 2021

Filed:

Nov. 03, 2017
Applicant:

Auckland Uniservices Limited, Auckland, NZ;

Inventors:

Swarnalatha Akuratiya Gamage, Auckland, NZ;

Peter Robin Shepherd, Auckland, NZ;

Jack Urquhart Flanagan, Auckland, NZ;

Gordon William Rewcastle, Auckland, NZ;

Andrew James Marshall, Auckland, NZ;

Christina Maree Buchanan, Auckland, NZ;

Guo-Liang Lu, Auckland, NZ;

Muriel Bonnet, Auckland, NZ;

Stephen Michael Frazer Jamieson, Auckland, NZ;

William Alexander Denny, Auckland, NZ;

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07D 311/86 (2006.01); C07D 219/08 (2006.01); C07D 335/16 (2006.01); C07D 405/06 (2006.01); C07D 405/12 (2006.01); C07D 405/14 (2006.01); C07D 409/02 (2006.01); C07D 221/04 (2006.01); C07D 409/12 (2006.01); C07D 335/18 (2006.01); A61K 45/06 (2006.01);
U.S. Cl.
CPC ...
C07D 311/86 (2013.01); C07D 219/08 (2013.01); C07D 221/04 (2013.01); C07D 335/16 (2013.01); C07D 335/18 (2013.01); C07D 405/06 (2013.01); C07D 405/12 (2013.01); C07D 405/14 (2013.01); C07D 409/02 (2013.01); C07D 409/12 (2013.01); A61K 45/06 (2013.01);
Abstract

Disclosed are tricyclic heterocyclic compounds having kinase inhibitory activity, pharmaceutical compositions and kits comprising the compounds, and use of the compounds in the treatment of or in medicaments for the treatment of various diseases and conditions. In particular, disclosed are tricyclic heterocyclic compounds of the formula (I) having CSF-1R (c-FMS kinase) inhibitory activity and their use in the treatment of various diseases and conditions, such as those mediated by CSF-1R, including proliferative or neoplastic diseases and conditions, including cancers, and bone, inflammatory, and autoimmune diseases and conditions.


Find Patent Forward Citations

Loading…